Nathalie Landry | Executive Vice President
Medicago | Canada

Nathalie Landry, Executive Vice President, Medicago

Ms. Landry oversees a multidisciplinary team in charge of preclinical and clinical studies, development of analytical methods and product characterization. Her group has conducted several clinical trials in the United States and Canada evaluating both pandemic and seasonal plant-made Influenza Virus-Like Particle (VLP) vaccine candidates. She is also actively involved in identifying and demonstrating the competitive advantages of plant-made products.  She represents the company at numerous international conferences and meetings and is co-author of several scientific publications and patents. She joined Medicago in 2000 as Director of Strategic Development, managing business development activities as well as intellectual property. In 2004, she became Senior Director of Product Development, managing the multidisciplinary team producing various recombinant proteins in plants, was named Vice-President in 2007, and was named Executive Vice-President in 2016.
Prior to joining Medicago she worked for a start-up biotech company developing and producing anticancer compounds, holding various positions such as scientist, intellectual property manager and director of operations.  She has more than 20 years of experience in the biotech industry. Ms. Landry earned a Master’s in microbiology-immunology in 1989 and an MBA in 1997, both from Laval University.


Oct 29th Day 1 @ 15:15

Update in the clinical development of a plant-derived quadrivalent Virus-Like Particles influenza vaccine

last published: 16/Sep/19 14:05 GMT

back to speakers

Sign Up for Event Updates